- Full Year 2023 Medacta Group SA Earnings Call TranscriptMar 13, 2024€78.81Earnings
- Full Year 2023 Medacta Group SA Corporate Sales Call TranscriptFeb 02, 2024
- Half Year 2023 Medacta Group SA Earnings Call TranscriptSep 22, 2023€78.81Earnings
- Half Year 2023 Medacta Group SA Corporate Sales Call TranscriptJul 28, 2023
- Full Year 2022 Medacta Group SA Earnings Call TranscriptMar 17, 2023€78.81Earnings
- Q4 2022 Medacta Group SA Unaudited Top-Line Figures Call TranscriptFeb 03, 2023
- Half Year 2022 Medacta Group SA Earnings Call TranscriptSep 09, 2022€78.81Earnings
- Half Year 2022 Medacta Group SA Earnings Call TranscriptJul 29, 2022€78.81Earnings
- Full Year 2021 Medacta Group SA Earnings Call TranscriptMar 11, 2022€78.81Earnings
- Q4 2021 Medacta Group SA Corporate Sales Call TranscriptJan 20, 2022
- Half Year 2021 Medacta Group SA Earnings Call TranscriptSep 10, 2021€78.81Earnings
- Half Year 2021 Medacta Group SA Corporate Sales Call TranscriptJul 20, 2021
- Full Year 2020 Medacta Group SA Earnings Call TranscriptMar 31, 2021€78.81Earnings
- Full Year 2020 Medacta Group SA Corporate Sales Call TranscriptJan 21, 2021
- Half Year 2020 Medacta Group SA Earnings Call TranscriptSep 07, 2020€78.81Earnings
- Half Year 2020 Medacta Group SA Earnings Call TranscriptJul 22, 2020€78.81Earnings
- Full Year 2019 Medacta Group SA Earnings Call TranscriptApr 06, 2020Earnings
Full Year 2020 Medacta Group SA Corporate Sales Call Transcript
Dear, ladies and gentlemen, welcome to the conference call of Medacta Group SA on the 2020 full year unaudited top line figures. At our customers' request, this conference will be recorded. (Operator Instructions)
May I now hand you over to the CEO of Medacta, Francesco Siccardi, who will lead you through this conference. Please go ahead.
Thank you very much for your introduction, and welcome to this full year 2020 preliminary unaudited top line figures presentation. I'm with Corrado Farsetta, our CFO; and Gianna La Rana, our Investor Relator.
So if we go to the first slide, you can see Medacta did perform pretty well in the second half of the year, with a very good acceleration in the second semester that was able to almost completely compensate the H1 results. So full year revenues hit EUR 302.5 million, only 2% on a constant currency basis behind last year. And given the circumstances, I have to say, I'm pretty pleased.
The second
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)